Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL725654 | 1.00 | ALDH1A1 (0.57) | ALDH1A1KDM4EPDK1MAPTHTT | |
| SCHEMBL725331 | 0.77 | ALDH1A1 (0.75) | ALDH1A1KDM4EPDK1MAPTHTT | |
| SCHEMBL9533498 | 0.70 | ALDH1A1 (0.81) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL3335215 | 0.69 | ALDH1A1 (0.72) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL3335212 | 0.69 | ALDH1A1 (0.72) | ALDH1A1KDM4EMAPTHTTCYP1A2 | |
| SCHEMBL17776430 | 0.68 | PDK1 (0.56) | ALDH1A1KDM4EPDK1CYP1A2GLRA1 | |
| SCHEMBL2933380 | 0.68 | PDK1 (0.56) | ALDH1A1KDM4EPDK1CYP1A2GLRA1 | |
| SCHEMBL15788160 | 0.68 | PDK1 (0.56) | ALDH1A1KDM4EPDK1CYP1A2GLRA1 | |
| SCHEMBL27696744 | 0.67 | PDK1 (0.60) | ALDH1A1PDK1GLRA1 | |
| SCHEMBL23169396 | 0.65 | ALDH1A1 (0.70) | ALDH1A1KDM4EMAPTHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2432321-B1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-06-14 | — | — | EP | disclosed |
| US-8410095-B2 | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2432321-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-03-01 | — | — | US | disclosed |
| WO-2010135504-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053147-A1 | THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS | PIK3CD, PIK3CA, PI4KA | ALDH1A1 2476/4885KDM4E 3250/4885PDK1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.